Category Archives: Business of Biotech

Novavax, Inc. (NASDAQ:NVAX) has received a Small Business and Innovation Research grant from the National Institute of Allergy and Infectious Diseases. The grant will support a segment of the Company’s preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine. As previously announced, Novavax has an RSV vaccine candidate in preclinical development, which is directed against a protein on the surface of the virus, the “F” or “fusion” protein. The grant, valued at approximately Read More >

Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a Canadian patent covering the chemical composition of the Company’s preclinical-stage peptide AL-209 and its use in protecting against Alzheimer’s disease and other degenerative diseases. The Company said AL-209 has demonstrated highly potent neuroprotective activity in preclinical studies where it has been shown to block the effect of toxic Read More >

Hana Biosciences (OTCBB:HNAB) has completed its previously disclosed private placement of units of its securities consisting of shares of common stock and warrants. Hana realized total gross cash proceeds of approximately $12.4 million. Net proceeds of the offering will be used to support completion of Hana’s pivotal Phase 2 clinical trial (rALLy) of Marqibo in adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in second relapse or who failed two Read More >

Biotech-Now’s Tracy Krughoff speaks with Joyce Cramer, president of the Epilepsy Therapy Project about the upcoming BIO Investor Forum and what this advocacy group looks for in terms of companies and projects. Listen to the podcast.

Targacept, Inc. (NASDAQ: TRGT) announced that the recently announced underwritten public offering of 2,200,000 shares of its common stock has been priced at a price to the public of $21.00 per share. As previously announced, Deutsche Bank Securities will act as sole manager for the offering and Targacept has granted Deutsche Bank Securities an option to purchase an additional 320,000 shares of common stock to cover over-allotments, if any. Read the release.